We suggest sole targeting of β-amyloid or tau may not be fruitful in AD as contributions from α-synuclein and TDP43 significantly modify disease pathogenesis—alternative disease-modifying targets are crucial. The gene discussed is MAPT; the disease is Alzheimer disease.